Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6
November 04 2020 - 8:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced that President and CEO Todd C. Brady, M.D., Ph.D., will
discuss Aldeyra’s novel therapeutic approaches to treating anterior
and posterior segment ocular disease at the Eyecelerator 2020
Virtual Conference on Friday, November 6, 2020. Dr. Brady’s
presentation is scheduled begin at 1:19 p.m. PT / 4:19 p.m. ET as
part of Company Showcase III, “Advancing Trials in the Public
Eye.”
The presentation will highlight data from clinical trials of
Aldeyra’s lead drug candidates, 0.25% reproxalap ophthalmic
solution and ADX-2191 (0.8% methotrexate intravitreal injection).
Reproxalap is in Phase 3 clinical trials for the treatment of dry
eye disease and allergic conjunctivitis, two of the largest markets
in ophthalmology. ADX-2191 is in Phase 3 testing for the prevention
of proliferative vitreoretinopathy (PVR), a rare but serious
sight-threatening retinal disease with no approved treatment.
Eyecelerator, a partnership between the American Academy of
Ophthalmology (AAO) and the American Society of Cataract and
Refractive Surgery (ASCRS), is designed to connect entrepreneurs,
investors, businesses and ophthalmologists to advance ophthalmic
innovation. To register for the Eyecelerator 2020 Virtual
Conference, visit https://www.eyecelerator.com/november-2020.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company
focused on the development of novel therapies with the potential to
improve the lives of patients with immune-mediated diseases. Two of
the company’s lead compounds, reproxalap and ADX-629, target
reactive aldehyde species (RASP), which are elevated in ocular and
systemic inflammatory disease and result in cytokine release via
activation of a broad array of inflammatory factors, including
NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being
evaluated in Phase 3 clinical trials in patients with dry eye
disease and allergic conjunctivitis. The company’s clinical
pipeline also includes ADX-2191, a dihydrofolate reductase
inhibitor in Phase 3 testing for proliferative vitreoretinopathy,
and ADX-1612, a chaperome inhibitor in development for COVID-19 and
ovarian cancer. For more information, visit
https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201104005121/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024